Special Bulletin

For professional and facility providers

August 21, 2023

HEDIS Measure: Avoidance of Antibiotic Treatment for Acute Bronchitis/Bronchiolitis

Overprescribing antibiotics is a major health concern in the United States. Antibiotic resistance has become one of the greatest health threats today. Antibiotic-resistant infections can be more difficult to treat and pose a threat to patient safety, which can lead to life-threatening illness as well as potential death.¹

Healthcare Effectiveness Data and Information Set (HEDIS®) Measure

Complying with the HEDIS quality measure **Avoidance of Antibiotic Treatment for Acute Bronchitis/Bronchiolitis (AAB)** occurs when patients three months and older — with a diagnosis of acute bronchitis (J20X) or bronchiolitis (J21X) — are <u>not</u> dispensed an antibiotic on the day of visit or within three days after. Noncompliance occurs when antibiotics are prescribed unnecessarily.

Exclusions

There are some competing and co-morbid diagnoses that will **exclude** the member from the AAB measure, including: acute pharyngitis, tonsillitis, suppurative otitis media, sinusitis, pneumonia, disease upper respiratory tract, acute lymphangitis, urinary tract infection (UTI), cancer, chronic obstructive pulmonary disease (COPD), HIV, respiratory failure, tuberculosis (TB), among others.

After examination, if a patient medically requires an antibiotic prescription due to a competing or co-morbid diagnosis, document the additional ICD-10 code on the claim.

Below are strategies to consider that might help improve physician performance related to the AAB HEDIS measure:

- Avoid prescribing antibiotics for certain illnesses such as acute bronchitis, without pneumonia, when there is
 no comorbidity of COPD, pulmonary fibrosis, or other chronic lung disease.
- Inform patients of the potential side effects and adverse events related to antibiotic use, even when such antibiotics are necessary and appropriate.

Antibiotic prescribing is a complex issue, but simple changes can potentially create a significant impact. For additional education on antibiotic stewardship, click here for free courses and webinars from the Centers for Disease Control and Prevention (CDC).

References

¹Sanchez GV, Fleming-Dutra KE, Roberts RM, Hicks LA. Core Elements of Outpatient Antibiotic Stewardship. MMWR Recomm Rep 2016;65(No. RR-6):1–12. DOI: http://dx.doi.org/10.15585/mmwr.rr6506a1 Highmark does not recommend particular treatments or health care services. This information is not intended to be a substitute for professional medical advice, diagnosis, or treatment. You should determine the appropriate treatment and follow-up with your patient. Coverage of services is subject to the terms of each member's benefit plan. This information is issued on behalf of Highmark Blue Shield and its affiliated Blue companies, which are independent licensees of the Blue Cross Blue Shield Association.

Additionally, state laws and regulations governing health insurance, health plans and coverage may apply and will vary from state to state.

Highmark Inc. d/b/a Highmark Blue Shield and certain of its affiliated Blue companies serve Blue Shield members in 21 counties in central Pennsylvania and 13 counties in northeastern New York. As a partner in joint operating agreements, Highmark Blue Shield also provides services in conjunction with a separate health plan in southeastern Pennsylvania. Highmark Inc. or certain of its affiliated Blue companies also serve Blue Cross Blue Shield members in 29 counties in western Pennsylvania, 13 counties in northeastern Pennsylvania, the state of West Virginia plus Washington County, Ohio, the state of Delaware, and 8 counties in western New York. All references to Highmark in this document are references to Highmark Inc. d/b/a Highmark Blue Shield and/or to one or more of its affiliated Blue companies.

The Healthcare Effectiveness Data and Information Set (HEDIS®) is a registered trademark of National Committee of Quality Assurance (NCQA).

